DexCom (NASDAQ:DXCM) Stock Gets Price Target Increase from JPMorgan Chase & Co.

Key Points

• JPMorgan raised DexCom’s price target from $82 to $85 while maintaining a “neutral” rating, implying approximately 3.29% upside from the prior close.
• Analyst sentiment remains broadly positive: DexCom has an average “Buy” rating and a consensus price target of $92.91, with Barclays, RBC, Argus, TD Cowen and Stifel Nicolaus also issuing bullish targets.
• DexCom exceeded quarterly expectations, reporting $0.73 in earnings per share and $1.34 billion in revenue, while revenue increased 11.1% year over year. Insiders sold shares valued at roughly $2.1 million during the quarter, a potential cautionary signal.

DexCom (NASDAQ:DXCM - Get Free Report) had its target price hoisted by equities research analysts at JPMorgan Chase & Co. from $82.00 to $85.00 in a research report issued on Friday, Benzinga reports. The firm currently has a "neutral" rating on the medical device company's stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 3.29% from the stock's previous close.

Other equities analysts have also issued research reports about the stock. Royal Bank Of Canada restated an "outperform" rating and set a $105.00 target price (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Barclays increased their price target on DexCom from $115.00 to $120.00 and gave the company an "overweight" rating in a research report on Friday. TD Cowen reissued a "buy" rating and issued a $95.00 price target on shares of DexCom in a research note on Friday, September 18th. Argus boosted their target price on DexCom from $86.00 to $96.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. Finally, Stifel Nicolaus set a $95.00 price objective on DexCom and gave the company a "buy" rating in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, DexCom currently has an average rating of "Buy" and a consensus target price of $92.91.

DexCom Stock Performance

Shares of DexCom stock traded up $2.36 during trading on Friday, reaching $82.29. The company's stock had a trading volume of 8,637,222 shares, compared to its average volume of 5,033,590. The firm has a market cap of $31.05 billion, a PE ratio of 32.53, a P/E/G ratio of 1.32 and a beta of 1.48. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The business's 50-day moving average price is $85.98 and its 200-day moving average price is $74.60. DexCom has a 52 week low of $54.11 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the prior year, the firm earned $0.61 earnings per share. The company's revenue was up 11.1% compared to the same quarter last year. Equities analysts forecast that DexCom will post 2.64 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president directly owned 146,828 shares in the company, valued at $12,226,367.56. The trade was a 2.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the completion of the sale, the director directly owned 29,293 shares of the company's stock, valued at $2,461,783.72. The trade was a 18.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 24,822 shares of company stock valued at $2,090,833. 0.28% of the stock is owned by company insiders.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ascentis Independent Advisors acquired a new stake in shares of DexCom during the first quarter worth approximately $25,000. Latitude Advisors LLC acquired a new position in DexCom in the third quarter valued at $32,000. Hilton Head Capital Partners LLC lifted its holdings in shares of DexCom by 242.3% in the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company's stock worth $33,000 after purchasing an additional 269 shares in the last quarter. Wellington Grp LLC increased its position in shares of DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after acquiring an additional 475 shares during the last quarter. Finally, Elevation Wealth Partners LLC boosted its holdings in DexCom by 61.0% in the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company's stock worth $35,000 after buying an additional 152 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company's product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.